Wesfarmers Ltd (ASX: WES) has been a compelling ASX dividend share for a number of years, and that could continue to be the case, based on projected payouts.

Wesfarmers is the business behind a number of leading Australian retail names, including Bunnings, Kmart, Officeworks, Priceline, Target, and others.

It also has a healthcare division and a chemicals, energy and fertiliser segment called WesCEF, which includes its lithium mining operations.

The company has regularly produced impressive results for shareholders and FY26 was no different with solid underlying performance.

In the 2026 financial year, Wesfarmers reported that underlying earnings per share (EPS) grew by 8.3% following 3.4% revenue growth. Bunnings Group saw earnings growth of 5.1% to $2.45 billion and Kmart Group saw earnings growth of 6% to $1.1 billion.

FY27

The company’s FY27 has started off solidly, with good sales growth for both Bunnings Group and Kmart Group. Those are the two core earnings drivers of the business, so it’s good to see the company has started FY26 in a good position.

Wesfarmers said that in the first seven weeks of FY27, Bunnings’ sales growth was slightly stronger compared to the second half of FY26. Kmart Group sales growth was “in line” with the second half of FY26.

Based on that trading update and commentary on the progress of the rest of the business (including the lithium segment), the projection on CommSec suggests Wesfarmers could grow EPS again in FY27 by around 10%.

However, the current projection suggests the business could deliver an annual dividend per Wesfarmers share of $2.40. That translates into a potential grossed-up dividend yield of 4.3%, including franking credits.

FY28

The forecast suggests that Wesfarmers could increase its payout and earnings in the following financial year.

According to the projection on CommSec, the company is projected to pay an annual dividend per Wesfarmers share of approximately $2.61 in FY28. This would translate into a possible grossed-up dividend yield of 4.7%, including franking credits.

Depending on what happens with the lithium price, the Wesfarmers WesCEF division could play an important role in overall earnings generation.

FY29

For the final financial year of this series of projections, the annual payout could get even better.

According to the projection on CommSec, the business could pay an annual dividend per Wesfarmers share of $2.71 in the 2029 financial year.

If the business does deliver that level of passive income, it would translate into a grossed-up dividend yield of 4.9%, including franking credits.

I think it’s one of the most impressive ASX blue-chip shares for dividends, though it’s certainly not cheap at this valuation.

The post Here’s the dividend forecast out to 2029 for Wesfarmers shares appeared first on The Motley Fool Australia.

More reading

• How to build an ASX portfolio you do not need to check every day
• Buy, hold, sell: Netwealth, Sigma Healthcare, and Wesfarmers shares
• Everything you need to know about the Wesfarmers dividend
• 3 ASX 200 dividend shares that just upped their payouts
• Why Wesfarmers, Mineral Resources and Qantas shares are turning heads on Thursday

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The GenusPlus Group Ltd (ASX: GNP) share price is in focus today after the company announced it will begin construction on the first stage of the TasNetworks North West Transmission Developments project, with total works valued at around $750 million.

What did GenusPlus report?

• TasNetworks has issued a Notice to Proceed to GenusPlus for the Construction Phase of NWTD Stage 1
• Construction work is set to commence immediately and is planned for completion in 2029
• Total project value is approximately $750 million, including Early Works and Early Contractor Involvement phases ($122 million)
• The project covers essential power infrastructure in Tasmania

What else do investors need to know?

The announcement follows several earlier updates from GenusPlus about its agreements with TasNetworks, most recently on 8 May 2026. The project is a major contract win for GenusPlus and represents a significant milestone in its growth, given the scale and long-term nature of the work.

GenusPlus is set to play a central role in delivering critical infrastructure for Tasmania, aiming to create local employment and engage Tasmanian suppliers. This contract demonstrates the company’s ongoing strength in the utilities and infrastructure sector across Australia.

What did GenusPlus management say?

GenusPlus Managing Director, David Riches, said:

Genus has worked closely with TasNetworks to reach this important milestone; and with the start of construction imminent we’re proud to move into the next phase of delivering this critical infrastructure for Tasmania and Australia. We’re committed to creating opportunities for Tasmanians throughout the project, from employing local people to engaging Tasmanian business and suppliers. By combining Genus’ capability and experience with local knowledge and expertise, we can deliver lasting value for the community.

What’s next for GenusPlus?

GenusPlus will now shift focus to delivering the construction phase of the TasNetworks NWTD project, with works scheduled until 2029. The company looks set to benefit from its expanded role as an essential service provider in the power and infrastructure sector.

Investors can expect ongoing updates on project milestones and further information about GenusPlus’ strategy to collaborate with local businesses and deliver benefits to both Tasmania and broader Australia.

GenusPlus share price snapshot

Over the past 12 months, GenusPlus shares have risen 66%, outperforming the All Ordinaries Index (ASX: XAO).

View Original Announcement

The post GenusPlus gets green light for $750m TasNetworks build appeared first on The Motley Fool Australia.

More reading

• Three ASX shares set to rise up to 47% – Expert
• GenusPlus Group FY26 earnings: Record results and outlook

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended GenusPlus Group. The Motley Fool Australia has recommended GenusPlus Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

4DMedical Ltd (ASX: 4DX) shares have been among the best performers on the S&P/ASX 200 index (ASX: XJO) over the past 12 months.

During this time, the medical technology company’s shares have risen a staggering 360%.

But if you thought the gains may be over, think again.

That’s because the team at Bell Potter believes there are still more market-beating returns on offer here over the next 12 months.

What is the broker saying?

Bell Potter notes that 4DMedical released its full-year results last week. And while the company only revealed modest revenue from its lung imaging technology, the broker believes the initial traction is highly meaningful. It said:

Product revenues of $6.9m includes $1.6m in fee for service revenues which we understand includes a portion of revenues billed for CT:VQ on a fee per scan basis. While the quantum of revenues is modest, we regard this initial traction in fee for service revenues as highly meaningful and we expect these revenues will grow exponentially in the coming quarters as awareness grows. 

Elsewhere, the company reported a normalised loss of $33.0m (FY25 loss $35.2m) and net operating cash burn of $31.3m. First revenues are yet to be earned at Simonmed, however, the five academic medical centres contracted for CT:VQ are each using the product on a regular basis.

Looking ahead, the broker sees ongoing traction with clinicians in the US as its major catalyst. It explains:

The major catalyst is the ongoing traction with clinicians in the US. There continues to be a ground swell of support for adoption of CT:VQ particularly amongst pulmonary specialists and interventional pulmonologists in academic hospitals. Inevitably this should radiate to other physicians as evidenced by the Simonmed deal and to some extent in Australia.

Big potential returns for 4DMedical shares

According to the note, in response to the company’s results, the broker has retained its speculative buy rating and $6.00 price target on 4DMedical shares.

Based on its current share price of $3.64, this implies potential upside of approximately 65% for investors over the next 12 months.

To put that into context, a $10,000 investment would turn into around $16,500 by this time next year if Bell Potter is on the money with its recommendation.

Commenting on its bullish view of the stock, the broker said:

4DX enters FY27 with good momentum at large hospital groups in the US. We expect on going revenue traction throughout the course of the year. Maintain Buy (Speculative) rating.

All in all, this could make 4DMedical worth considering if you have a high tolerance for risk and want exposure to the medical technology industry.

The post Why 4DMedical shares could still rise 65% appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• 5 things to watch on the ASX 200 on Monday
• 4DMedical share price rises as FY26 revenue climbs, losses moderate
• Here are the top 10 ASX 200 shares today
• These are the 10 most shorted ASX shares

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.